

Title (en)

A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVES OR THEIR SALTS, AND ALENDRONIC ACID OR ITS SALT

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VERHINDERUNG ODER BEHANDLUNG VON OSTEOPOROSE MIT BENZAMIDINDERIVATEN ODER DEREN SALZEN SOWIE MIT ALENDRONSÄURE ODER DEREN SALZEN

Title (fr)

COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR OU TRAITER L'OSTÉOPOROSE À BASE DE DÉRIVÉS DE BENZAMIDINE OU DE SELS DE CEUX-CI, ET D'ACIDE ALENDRONIQUE OU DE SELS DE CELUI-CI

Publication

EP 2307015 A4 20120516 (EN)

Application

EP 09803174 A 20090731

Priority

- KR 2009004277 W 20090731
- KR 20080075792 A 20080801

Abstract (en)

[origin: WO2010013969A2] The present invention relates to a pharmaceutical composition for preventing and treating osteoporosis, comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidinium, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidinium, or salts thereof, and alendronic acid or a salt thereof. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidinium, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidinium, or salts thereof and alendronic acid or a salt thereof exhibits excellent inhibitory effect on osteoclast differentiation, as compared to each individual treatment, thereby being useful for the prevention or treatment of osteoporosis.

IPC 8 full level

A61K 31/426 (2006.01); **A61K 31/663** (2006.01); **A61P 19/10** (2006.01)

CPC (source: EP KR)

A61K 31/426 (2013.01 - EP KR); **A61K 31/663** (2013.01 - EP KR); **A61P 19/10** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)

- [E] WO 2010013975 A2 20100204 - DONG WHA PHARM CO LTD [KR], et al
- [Y] WO 2006004369 A1 20060112 - DONG WHA PHARM IND CO LTD [KR], et al
- [Y] WO 03007947 A1 20030130 - DONG WHA PHARM IND CO LTD [KR], et al
- [Y] GREENSPAN SUSAN L ET AL: "Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: A randomized controlled trial.", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 289, no. 19, 21 May 2003 (2003-05-21), pages 2525 - 2533+CORR, XP002672632, ISSN: 0098-7484
- [Y] BLACK D M ET AL: "THE EFFECTS OF PARATHYROID HORMONE AND ALENDRONATE ALONE OR IN COMBINATION IN POSTMENOPAUSAL OSTEOPOROSIS", NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 13, 25 September 2003 (2003-09-25), MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, pages 1207 - 1215, XP009045315, ISSN: 1533-4406, DOI: 10.1056/NEJMOA031975
- See references of WO 2010013969A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)

WO 2010013969 A2 20100204; **WO 2010013969 A3 20100527**; CA 2732863 A1 20100204; CN 102149380 A 20110810; CN 102149380 B 20121205; EP 2307015 A2 20110413; EP 2307015 A4 20120516; JP 2011529875 A 20111215; KR 20100014173 A 20100210

DOCDB simple family (application)

KR 2009004277 W 20090731; CA 2732863 A 20090731; CN 200980133563 A 20090731; EP 09803174 A 20090731; JP 2011521043 A 20090731; KR 20090070534 A 20090731